Target Audience and Goal Statement
This activity is intended for oncologists, surgeons, pathologists, and other healthcare professionals who treat patients with
head and neck cancer.
The goal of this activity is to discuss the role of immunotherapy in the treatment of recurrent or metastatic head and neck
squamous cell carcinoma (HNSCC) and to highlight strategies for working effectively with patients to achieve optimal care.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding the:
- Recent clinical evidence for the use of immune checkpoint inhibitors, particularly factors that may influence individualized
treatment choices
- Use of strategies to optimize patient-centered management when determining a treatment plan for patients with HNSCC
Disclosures
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of
an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant
financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial
relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food
and Drug Administration, at first mention and where appropriate in the content.
Moderator(s)

-
Robert L. Ferris, MD, PhD
Professor and Chief, Division of Head and Neck Surgery, Departments of Otolaryngology, Radiation Oncology, and Immunology;
Co-leader, Cancer Immunology Program, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Disclosures
Disclosure: Robert L. Ferris, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Merck & Co., Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company
Dr Ferris does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Dr Ferris does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

-
Laura Q.M. Chow, MD
Associate Professor, University of Washington; Associate Director, Phase I Developmental Therapeutics Program; Associate Member,
Fred Hutchison Cancer Research Center; Attending Physician, Seattle Cancer Care Alliance, Seattle, Washington
Disclosures
Disclosure: Laura Q.M. Chow, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Merck &
Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi/Genzyme Corporation; Seattle Genetics, Inc.
Dr Chow does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the
FDA for use in the United States.
Dr Chow does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA
for use in the United States.
Steering Committee
-
Jeffrey S. Weber, MD, PhD
Professor of Medicine; Deputy Director, Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York
Disclosures
Disclosure: Jeffrey S. Weber, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Altor Bioscience Corp.; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers
Squibb Company; Celldex Therapeutics, Inc.; CytomX Therapeutics; GlaxoSmithKline; Merck & Co., Inc.
Received grants for clinical research from: Acetylon Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Mirati Therapeutics,
Inc.
Owns stock, stock options, or bonds from: Altor Bioscience Corp.; Celldex Therapeutics, Inc.; CytomX Therapeutics
-
Robert L. Ferris, MD, PhD
-
Ramaswamy Govindan, MD
Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine; Co-Director, Section of Medical
Oncology, Siteman Cancer Center, Barnes-Jewish Hospital, St. Louis, Missouri
Disclosures
Disclosure: Ramaswamy Govindan, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ARAID; Astellas Pharma, Inc.; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim
Pharmaceuticals, Inc.; Celgene Corporation; Clovis Oncology; Genentech, Inc.; GlaxoSmithKline; Helsinn Therapeutics, Inc;
Roche
Served as a speaker or member of a speakers bureau for: Baxalta; Roche
-
Antoni Ribas, MD, PhD
Professor, Department of Medicine, Division of Hematology/Oncology; Director, Tumor Immunology Program, Jonsson Comprehensive
Cancer Center, University of California, Los Angeles
Disclosures
Disclosure: Antoni Ribas, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Genentech, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation
Owns stock, stock options, or bonds from: Compugen; CytomX Therapeutics; FivePrime Therapeutics; Kite Pharma Inc.
-
Jared Weiss, MD
Assistant Professor of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel
Hill, North Carolina
Disclosures
Disclosure: Jared Weiss, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Biodesix, Inc.; Clovis Oncology; EMD Serono, Inc.;
Lilly; Pfizer Inc.
Received grants for clinical research from: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Celgene Corporation; Merck
& Co., Inc.; Novartis Pharmaceuticals Corporation
Editor(s)
-
Weiping Zou, MD, PhD
Charles B. de Nancrede Professor; Professor of Surgery, Immunology and Biology; Co-Director, Cancer Hematopoiesis and Immunology
Program; Co-Director, Immunologic Monitoring Core; Director, University of Michigan Surgical Oncology Research Training Program;
Director, Translational Research, Department of Surgery, University of Michigan School of Medicine, Ann Arbor, Michigan
Disclosures
Disclosure: Weiping Zou, MD, PhD, has disclosed no relevant financial relationships.
CME Reviewer(s)
Additional Planners/Reviewers
Peer Reviewer
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
Accreditation Statements
This activity has been planned and implemented by Medscape, LLC and the Society for Immunotherapy of Cancer. Medscape, LLC
is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE),
and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare
team.
For Physicians
-
Medscape, LLC designates this enduring material for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant
to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.
Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity
provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Aggregate participant data will be shared with commercial supporters of this activity.
Contact This Provider
For questions regarding the content of this activity, contact the
accredited provider for this CME/CE activity noted above. For technical
assistance, contact [email protected]
Instructions for Participation and Credit
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
- Read the target audience, learning objectives, and author disclosures.
- Study the educational content online or printed out.
- Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated
at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.